Solid tumours and malignant haemopathies
The tests carried out in the Cellular Haematology, Cytogenetics and Molecular Genetics departments of Eurofins Biomnis enable the optimum management of cancer patients (malignant haemopathies or solid tumours).
We offer a complete range of analytical tests allowing the diagnostic, prognostic and theranostic evaluation of all malignant haemopathies (chronic lymphoproliferative syndromes, myelomas, chronic myeloproliferative neoplasias, myelodysplastic syndromes, acute leukaemias, etc.) and a wide spectrum of solid tumours (breast, lung, colorectal & gastric cancers, melanomas, sarcomas, etc.).
The various departments employ state-of-the-art technology (10-colour flow cytometers, automatic metaphase finders, sequencing platforms…) operated by technicians specialised in clinical pathology.
Our physicians, pharmacists and clinical pathologists are members of the following societies: GFHC (French Cellular Haematology Group), SFH (French Haematology Society), AFC (French Cytometry Association), GFCH (Francophone Group for Cytogenetic Haematology), ACLF (Francophone Cytogeneticists Association), GFCO (French Group for Study of Cytogenetics in Oncology) and GBMHM (Molecular Biology Group for Haematological Malignancies).
The Cellular Haematology/Cytogenetics Department is fully accredited for all the analyses it performs, in accordance with the NF EN ISO 15189 standard.
More information
- Allergy
- T21 screening – NIPT – Pre-eclampsia – Fœtal biochemistry
- Cytogenetics
- Solid tumours and malignant haemopathies
- Genetics
- Infectiology
- Biochemistry
- Immunology
- Haematology
- Wellness & Preventive Health
- Analytical chemistry
- Assisted reproductive technology – Embryology – Sperm science
- Pathological anatomy and cytology (PAC)
- Empreintes génétiques